#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15712	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2033	765.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	1659	1659	T	832	T	762	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15712	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2033	765.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1393	1393	C	902	C	848	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29096	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3694	785.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1666	1666	A	910	A	860	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29096	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3694	785.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2300	2300	C	896	C	834	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29096	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3694	785.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2374	2374	A	944	A	888	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29096	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3694	785.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	2926	2926	C	928	C,A	872,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2324	folP	855	855	100.0	folP.l6.c30.ctg.1	1510	152.9	1	SNP	p	R229S	1	.	.	685	687	AGC	1026	1028	AGC	253;252;253	A;G,C;C	236;236,1;235	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6076	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3325	182.0	1	SNP	p	S91F	1	.	.	271	273	TTC	508	510	TTC	228;227;226	T;T;C	213;212;214	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6076	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3325	182.0	1	SNP	p	D95G	1	.	.	283	285	GGC	520	522	GGC	214;213;215	G;G;C	203;202;203	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6076	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3325	182.0	1	SNP	p	G95N	0	.	.	283	285	GGC	520	522	GGC	214;213;215	G;G;C	203;202;203	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1876	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1335	140.0	1	SNP	p	G45D	0	.	.	133	135	GGC	477	479	GGC	229;230;230	G,T;G;C,G	215,1;214;214,1	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1028	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c30.ctg.1	1021	100.1	0	.	n	.	0	A197.	DEL	197	197	A	550	550	A	217	A	211	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	539	5538	parC	2304	2304	99.83	parC.l15.c17.ctg.1	2962	186.3	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1676	1678	GCA	220;218;217	G;C;A	203;198;198	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	539	5538	parC	2304	2304	99.83	parC.l15.c17.ctg.1	2962	186.3	1	SNP	p	D86N	0	.	.	256	258	GAC	629	631	GAC	224;222;222	G;A;C	210;203;208	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	539	5538	parC	2304	2304	99.83	parC.l15.c17.ctg.1	2962	186.3	1	SNP	p	R87W	0	.	.	259	261	CGT	632	634	CGT	220;218;219	C;G;T	207;203;204	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	539	5538	parC	2304	2304	99.83	parC.l15.c17.ctg.1	2962	186.3	1	SNP	p	R87I	0	.	.	259	261	CGT	632	634	CGT	220;218;219	C;G;T	207;203;204	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	539	5538	parC	2304	2304	99.83	parC.l15.c17.ctg.1	2962	186.3	1	SNP	p	S87R	1	.	.	259	261	CGT	632	634	CGT	220;218;219	C;G;T	207;203;204	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	539	5538	parC	2304	2304	99.83	parC.l15.c17.ctg.1	2962	186.3	1	SNP	p	S88P	0	.	.	262	264	TCC	635	637	TCC	218;219;220	T;C;C	204;207;202	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4810	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2636	181.8	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1324	1326	TGC	197;197;198	T;G;C,T	181;183;182,1	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4810	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2636	181.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1534	1536	GGC	220;217;216	G;G;C,T	205;204;202,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	4268	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2265	187.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1194	1196	GCA	243;246;250	G;C;A	229;231;239	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4268	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2265	187.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1197	1199	ATC	251;250;253	A;T;C,T	234;237;237,1	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4268	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2265	187.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1209	1211	GTG	250;249;250	G;T;G	233;228;235	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4268	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2265	187.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1209	1211	GTG	250;249;250	G;T;G	233;228;235	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4268	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2265	187.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1713	1715	ACC	235;237;238	A;C,T;C	210;219,1;220	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4268	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2265	187.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1767	1769	GCG	209;208;206	G;C;G	185;170;177	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4268	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2265	187.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1767	1769	GCG	209;208;206	G;C;G	185;170;177	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4268	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2265	187.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1890	1892	GGC	182;182;181	G;G;C	172;171;169	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4268	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2265	187.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1899	1901	GGC	181;177;175	G;G;C	170;163;162	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4268	penA	1749	1749	99.94	penA.l15.c4.ctg.1	2265	187.2	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1917	1919	TCG	165;163;160	T,G;C;G	105,6;126;127	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5916	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3136	188.0	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1649	1651	CCG	218;219;219	C;C,T;G	196;199,1;199	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2542	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1846	136.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	476	476	C	165	C,T	156,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3162	porB1b	1047	1047	98.85	porB1b.l15.c17.ctg.1	1383	226.0	0	.	p	.	0	N38E	NONSYN	112	114	AAT	305	307	GAA	284;287;288	G;A;A	266;272;274	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3162	porB1b	1047	1047	98.85	porB1b.l15.c17.ctg.1	1383	226.0	0	.	p	.	0	N134D	NONSYN	400	402	AAT	593	595	GAT	257;260;258	G,A;A;T,G	240,1;242;237,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3162	porB1b	1047	1047	98.85	porB1b.l15.c17.ctg.1	1383	226.0	0	.	p	.	0	M141I	NONSYN	421	423	ATG	614	616	ATA	257;259;257	A;T;A,G	240;241;239,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3162	porB1b	1047	1047	98.85	porB1b.l15.c17.ctg.1	1383	226.0	0	.	p	.	0	P175S	NONSYN	523	525	CCA	716	718	TCA	242;243;246	T;C;A	222;225;229	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3162	porB1b	1047	1047	98.85	porB1b.l15.c17.ctg.1	1383	226.0	0	.	p	.	0	F215T	NONSYN	643	645	TTT	836	838	ACT	237;239;242	A,T;C;T	227,1;231;230	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3162	porB1b	1047	1047	98.85	porB1b.l15.c17.ctg.1	1383	226.0	0	.	p	.	0	A218V	NONSYN	652	654	GCC	845	847	GTG	236;234;235	G;T;G	224;221;224	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3162	porB1b	1047	1047	98.85	porB1b.l15.c17.ctg.1	1383	226.0	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1175	1177	GCA	261;261;263	G;C,G;A,G	246;249,1;250,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3162	porB1b	1047	1047	98.85	porB1b.l15.c17.ctg.1	1383	226.0	1	SNP	p	G120K	1	.	.	358	360	AAG	551	553	AAG	240;240;236	A;A;G	229;229;225	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3162	porB1b	1047	1047	98.85	porB1b.l15.c17.ctg.1	1383	226.0	1	SNP	p	D121N	0	.	.	361	363	GAC	554	556	GAC	241;238;236	G,A;A;C	226,1;225;224	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3162	porB1b	1047	1047	98.85	porB1b.l15.c17.ctg.1	1383	226.0	1	SNP	p	A121D	1	.	.	361	363	GAC	554	556	GAC	241;238;236	G,A;A;C	226,1;225;224	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11930	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4928	241.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2060	2062	AAT	282;278;277	A;A;T	271;268;262	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1218	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1004	120.4	1	SNP	p	V57M	1	.	.	169	171	ATG	535	537	ATG	260;262;264	A;T;G	252;251;254	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
